Microbix Biosystems: Buy Rating Amidst Revenue Challenges and Long-term Growth Potential

In a report released on August 15, David Martin PhD from Bloom Burton maintained a Buy rating on Microbix Biosystms, with a price target of C$0.50.

David Martin PhD has given his Buy rating due to a combination of factors, despite the current challenges faced by Microbix Biosystems. The company reported a decline in revenues for FY3Q-2025, primarily due to weaker sales in antigens and QAPs. The antigen sales were significantly impacted by reduced demand from China and a milder respiratory virus season, which led to lower testing volumes. However, David Martin anticipates that organic growth could return by FY2027 as market conditions stabilize.
Despite the setbacks, QAPs sales showed resilience, declining only slightly year-over-year. This was notable given the loss of development revenue from a major customer, QuidelOrthro. David Martin’s optimism for a Buy rating is likely influenced by the potential for recovery and growth in the coming years, as well as the company’s ability to navigate through current headwinds. The long-term outlook for Microbix remains positive, with expectations of improved performance as market dynamics evolve.